AstraZeneca said on Tuesday it will invest $300 million in a facility in Rockville, Maryland for discovery and development of cell therapies.
Artificial intelligence grabbed most of the headlines last year, but weight loss stocks were equally noteworthy. It grew slowly for several years but really went stratospheric last year.
AstraZeneca PLC (LSE:AZN) shares have continued their underperformance from the final quarter of last year into January, with Barclays identifying three major debates around the stock ahead of this w
Evaluate the expected performance of Astrazeneca (AZN) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metr
Sales of AstraZeneca's (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new indications.
AstraZeneca is one of the fastest-growing pharmaceutical companies. On February 8, 2024, the company will publish financial results for the 4th quarter of 2023. From a broader perspective, AstraZeneca
AstraZeneca PLC (LSE:AZN) recently committed to reporting how its business impacts nature as part of annual corporate results, but next Thursday's final results are not likely to focus on anything oth

3 No-Brainer Stocks to Buy With $500 Right Now

05:21am, Wednesday, 31'st Jan 2024
Wall Street's major stock indexes have oscillated between bear and bull markets in successive years since this decade began. Despite a strong performance from Wall Street in 2023, bargains can still b
AstraZeneca's (AZN) sBLA for Enhertu to treat metastatic HER2-positive solid tumors gets priority review status by the FDA. A final decision is expected in second-quarter 2024.
We expect GSK's specialty products like Arexvy, Cabenuva, Dovato, Bexsero, Trelegy Ellipta and Shingrix to drive fourth-quarter sales performance.
In the latest trading session, Astrazeneca (AZN) closed at $67.02, marking a +0.63% move from the previous day.
Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Data from a late-stage shows that AstraZeneca's (AZN) cancer combination therapy reduces the risk of disease progression or death in certain liver cancer patients by 23%.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
In the closing of the recent trading day, Astrazeneca (AZN) stood at $66.54, denoting a +0.03% change from the preceding trading day.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE